No products in the cart.
Oral remibrutinib hits Phase 3 primary endpoint for inducible hives
1. Oral remibrutinib successfully met its primary endpoint in the Phase III RemIND trial, delivering significant symptom relief for chronic ...
- Specialties
- All Specialties, All Recent Reports
- Cardiology
- Chronic Disease
- Dermatology
- Emergency
- Endocrinology
- Gastroenterology
- Imaging and Intervention
- Infectious Disease
- Nephrology
- Neurology
- Obstetrics
- Oncology
- Ophthalmology
- Pediatrics
- Pharma
- Preclinical
- Psychiatry
- Public Health
- Pulmonology
- Rheumatology
- Surgery
- Tools
- Pharma
- AI News
- The Scan+
- Classics™+
- Rewinds
- Partners
- Account
- Specialties
- All Specialties, All Recent Reports
- Cardiology
- Chronic Disease
- Dermatology
- Emergency
- Endocrinology
- Gastroenterology
- Imaging and Intervention
- Infectious Disease
- Nephrology
- Neurology
- Obstetrics
- Oncology
- Ophthalmology
- Pediatrics
- Pharma
- Preclinical
- Psychiatry
- Public Health
- Pulmonology
- Rheumatology
- Surgery
- Tools
- Pharma
- AI News
- The Scan+
- Classics™+
- Rewinds
- Partners
- Account
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
Recent Reports
- Higher ultra-processed food intake in young children is associated with adverse early behavioural outcomes
- Lower preoperative serum calcium is associated with increased risk of postoperative complications in patients undergoing orthopedic surgery
- Visual perturbation training may be superior to treadmill training for reduction of fall risk in Parkinson’s disease